Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.
Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling.
复制标题
DOI：
10.1186/s12885-018-4808-5
复制
发表时间：
2018-09-19
期刊：
影响因子：
3.8
通讯作者：
Fuller CD
中科院分区：
文献类型：
--
作者：
Ng SP;Bahig H;Wang J;Cardenas CE;Lucci A;Hall CS;Meas S;Sarli VN;Yuan Y;Urbauer DL;Ding Y;Ikner S;Dinh V;Elgohari BA;Johnson JM;Skinner HD;Gunn GB;Garden AS;Phan J;Rosenthal DI;Morrison WH;Frank SJ;Hutcheson KA;Mohamed ASR;Lai SY;Ferrarotto R;MacManus MP;Fuller CD
磁共振成像（MRI）提高了在头颈部癌症中肿瘤和软组织受累的可视化能力。使用先进的MRI，我们可以使用扩散加权成像来询问细胞密度，这是一种定量成像，可以在放射治疗期间使用，当弥漫性炎症反应排除PET成像时，也可以帮助目标描绘。循环肿瘤细胞（CTCs）测量与三维肿瘤定量表征的相关性可能潜在地允许选择性的、患者特异性反应适应的局部治疗升级或降级，并提高治疗比率，以最小的毒性治愈最多的患者。本研究为前瞻性观察性研究，收集治疗前的CT、MRI和PET/CT图像，治疗期间每周的连续MR成像和治疗后的CT、MRI和PET/CT图像。此外，在这些时间间隔内将采集血液样本进行生物标志物分析。CTC评估将使用fda批准的CellSearch®循环肿瘤细胞试剂盒（Janssen Diagnostics）在CellSave试管上进行，EDTA血液样本中的血浆将被收集，用去识别编号标记，并保存在- 80°C以供将来分析。本研究的主要目的是评估放疗期间粘膜头颈癌患者每周肿瘤反应动力学（肿瘤总量和MR信号变化）和循环肿瘤细胞的预后价值和相关性，并利用MRI预测治疗反应和临床结果。该研究将为CTCs（液体活检）和治疗过程中肿瘤特异性功能定量成像变化的应用提供里程碑式的信息，以指导未来患者的个性化治疗。结合来自ctc的生物信息和来自MRI的结构信息可能比单独使用任何一种方式提供更多的信息。此外，这项研究可能使我们能够确定放射治疗期间获得MR成像和/或ctc的最佳时间，以评估肿瘤反应，并为患者选择和分层提供指导，以制定未来的剂量增加或减少策略。Clinicaltrials.gov (NCT03491176)。注册日期：2018年4月9日。(回顾注册)。首位参赛者报名日期：2017年5月30日。
Magnetic resonance imaging (MRI) has improved capacity to visualize tumor and soft tissue involvement in head and neck cancers. Using advanced MRI, we can interrogate cell density using diffusion weighted imaging, a quantitative imaging that can be used during radiotherapy, when diffuse inflammatory reaction precludes PET imaging, and can assist with target delineation as well. Correlation of circulating tumor cells (CTCs) measurements with 3D quantitative tumor characterization could potentially allow selective, patient-specific response-adapted escalation or de-escalation of local therapy, and improve the therapeutic ratio, curing the greatest number of patients with the least toxicity. The proposed study is designed as a prospective observational study and will collect pretreatment CT, MRI and PET/CT images, weekly serial MR imaging during RT and post treatment CT, MRI and PET/CT images. In addition, blood sample will be collected for biomarker analysis at those time intervals. CTC assessments will be performed on the CellSave tube using the FDA-approved CellSearch® Circulating Tumor Cell Kit (Janssen Diagnostics), and plasma from the EDTA blood samples will be collected, labeled with a de-identifying number, and stored at − 80 °C for future analyses. The primary objective of the study is to evaluate the prognostic value and correlation of weekly tumor response kinetics (gross tumor volume and MR signal changes) and circulating tumor cells of mucosal head and neck cancers during radiation therapy using MRI in predicting treatment response and clinical outcomes. This study will provide landmark information as to the utility of CTCs (‘liquid biopsy) and tumor-specific functional quantitative imaging changes during treatment to guide personalization of treatment for future patients. Combining the biological information from CTCs and the structural information from MRI may provide more information than either modality alone. In addition, this study could potentially allow us to determine the optimal time to obtain MR imaging and/ or CTCs during radiotherapy to assess tumor response and provide guidance for patient selection and stratification for future dose escalation or de-escalation strategies. Clinicaltrials.gov (NCT03491176). Date of registration: 9th April 2018. (retrospectively registered). Date of enrolment of the first participant: 30th May 2017.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
11.5
作者：
Danila, Daniel C.;Heller, Glenn;Scher, Howard I.
通讯作者：
Scher, Howard I.
影响因子：
78.8
作者：
Pantel, Klaus;Alix-Panabieres, Catherine;Riethdorf, Sabine
通讯作者：
Riethdorf, Sabine
影响因子：
3.1
作者：
Cristofanilli, Massimo;Broglio, Kristine R.;Valero, Vicente
通讯作者：
Valero, Vicente
影响因子：
6.4
作者：
Shoultz-Henley, Sara;Garden, Adam S.;Fuller, Clifton D.
通讯作者：
Fuller, Clifton D.